Gold Mountain Mining Valuation
Is 5XFA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 5XFA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 5XFA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 5XFA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 5XFA?
Key metric: As 5XFA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 5XFA's PS Ratio? | |
|---|---|
| PS Ratio | 9.9x |
| Sales | CA$3.20m |
| Market Cap | CA$35.71m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 12.8x |
| Enterprise Value/EBITDA | -4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 5XFA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.6x | ||
DLX Delignit | 0.3x | 10.2% | €24.4m |
IBU IBU-tec advanced materials | 0.7x | 19.2% | €33.3m |
BNN BRAIN Biotech | 1.2x | 8.5% | €68.8m |
MGZ.H Mangazeya Mining | 0.2x | n/a | CA$45.1m |
5XFA Gold Mountain Mining | 9.9x | n/a | €35.7m |
Price-To-Sales vs Peers: 5XFA is expensive based on its Price-To-Sales Ratio (9.9x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does 5XFA's PS Ratio compare vs other companies in the European Metals and Mining Industry?
| 35 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 35 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 5XFA is expensive based on its Price-To-Sales Ratio (9.9x) compared to the European Metals and Mining industry average (0.7x).
Price to Sales Ratio vs Fair Ratio
What is 5XFA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 9.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 5XFA's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Tokuyama
JP¥196.7b
Produces and sells various chemical products in Japan.
TBT
JP¥16.60
7D
5.7%
1Y
14.5%
Ecora Resources
UK£162.5m
Operates as a natural resource royalty and streaming company in Australia, North and South America, Europe, and internationally.
HGR
UK£0.76
7D
1.5%
1Y
-28.3%
Arkema
€5.7b
Manufactures and sells specialty chemicals and advanced materials worldwide.
V1S
€74.55
7D
-4.4%
1Y
-19.9%